Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Timster...I'm not saying it doesn't hsppen just that it's not common for doctors to point patients to trials.
Yes side effects of chemo can be horrendous but the radiotherapy can be awful too.
Sorry to hear your SiL had such a bad time.
Kevin1977...I'm extremely sorry to hear about your friend. My advise is he should ask if there are any suitable trials available. If he doesn't feel comfortable with this route ( quite understandable) he should make sure his doctor gets him the fastest treatment possible. Don't let him be fobbed off. If he can't be treated quickly near to where he lives he should insist on going to other centres which can start treatment quickly and he should be prepared to travel. Speed is now priority. I wish him all the very best.
Timster...'He'd be given options of applicable trials from his physician when given the horrible prognosis.'
In my experience this is highly unlikely...doctors don't naturally point patients to trials. Patients who ask about trials may get pointed.
Thompi...thanks for your post...I'm posting it up again under a new heading just incase some missed it. It clearly explains why they are trying out a 2 weekly dose...it seems less could be more...
CC is referring to slide 13: Toxicities with AVA6000 Demonstrate a Dose Relationship
“And so this table then describes for you a critical observation, as it provides then our first evidence that using a lower dose, and potentially shortening the interval between doses to every two weeks could enhance the anti-tumour activity by delivering more drug, increasing the dose intensity but with little to no severe toxicity. There are examples of this kind of approach in the clinic. Probably the most relevant here is the taxane Paclitaxel in the field of oncology. When Paclitaxel is administered in some settings in an every three-week regimen at a higher dose it's highly toxic, it's effective. However, when it was moved to an every weekly regimen with a lower dose, the toxicity was minimised and actually enhanced the activity. This weekly regimen is used more in the clinic, both are still used. But this is the rationale for these new dose cohorts of every two weeks dosing and it's based on the observations in this slide.”
https://youtu.be/eqj0hhgmX6U?si=tER5X1gdtec3L9Cd
Hurst10...all these deals are for companies with more behind them than Avacta right now...be it sales, contracts, product pipelines in trial or commercialised. You're not comparing apples with apples.
Energyshares...yes I had read the Feb RNS and noted the plural tumour comment made by CC...
As AACR falls about 1 year from C5 dosing and will be through C7 and possibly beyond if they are continuing to dose those beyond the trial, I am hoping they will put some emphasis on OS.
The 2W trial has, IMHO, been introduced because of OS/observed tumour reductions/no MTD at 3 times normal Dox levels/limited side effects again at 3 times Dox levels.
Everyone knows Cancer is always a race against time...the longer the intervals between treatments the more chance the more chance of resistancy setting in which is the biggest problems combined with damage to other vial organs (heart being the major one in the case of Dox).
So...how will AVA6000 perform on a 2W basis...that's the next biggest factor in this very early stage SAFETY/DOSING trial and what new definitive data will they Post at AARC regading the 3W trial.
B2HS2L...No I was referring to OS...overall survival.
C5 first dose was April 23...
So my question is...are any of the patients still alive/in remission???? If so, this would be huge as they were all at end of life
B2HS2L...'IMO AACR info has to include Q3W data - cohorts 5,6, & 7, else why bother attending unless you are going to poster info that is publicly available from presentations.'
Sure it will. Even better if they are able to confirm patient(s) still surviving too...
'Monetising Diagnostics through divestment would also bring in non-dilutive funding, but may, in our view, be targeted for later in this period, giving management time to embed the acquisitions, and improve the sales and profitability trajectory. As usual in such situations, we suspend our valuation and forecasts; for context our last published Avacta valuation was £672m (equivalent to 237p per share).'
Gje306... in my experience it can take a few weeks before starting chemo...and as you say some patients may be nervous but they are not getting a new drug...they are getting dox in a new carrier which has already show it targets the dox at the tumour and substantially reduces the serious side effects.
It's more likely difficult to find patients that meet all the strict trial criteria...which is often the case with trials znd reason they can take longer than initially thought.
Gje306...the have said readouts are due late Q2..so June 2024. As I've said before they probably got all the screening sorted and were just waiting for the fundraiser to complete. Now they have to get their skates on...
Significant Newsflow
The Company is anticipating the progression of its clinical development and research stage programmes to important value inflection points across 2024 and 2025, which includes key deliverables for the pre|CISIONTM pipeline:
· AVA6000:
o Read out of two-weekly and three-weekly dose escalation study data in late Q2 2024;
o Presentation of Phase 1 three-weekly study clinical data at AACR 2024 in April 2024; and
o Establish recommended Phase 2 dose in Q3 2024, initiating the dose expansion phase in the US in H2 2024, followed by the Phase 2 study, subject to funding and FDA approval.
· AVA3996:
o Complete IND enabling studies and submit IND/CTA application in Q4 2024/Q1 2025; and
o Initiate Phase 1a dose escalation study in the first half of 2025.
· pre|CISION? pre-clinical pipeline:
o Next clinical candidate to be selected Q1 2025;
o Tumour microenvironment activated drug conjugate clinical candidate to selected in the second half of 2025; and
o Further expand pipeline;
PL75....'Suspect they're all at it. Sitting about waiting for AIM companies to give them the chance to make a few bob at PIs expense'...
Errrrr! I can't believe you've only just realised that's why II's love fundraisers so much...for this very reason that's why I was , and still am, hoping that the European Speciality Fund is the likes of Medicxi because they would be in for the long haul.
Did someone say there was a 40 day rule which ends on 9 April?
So let's see what that brings in the way of news or is it just a postr of what we've already been told.
DTW...' the majority of fund managers do not have an understanding of the science at AVCT.'...they know very little about most of the companies they are invested in. Unfortunately well researched PI's tend to think II's must be the same or that they may know more. In my experience this s not the case unless they've gone Inside and even the information the might get then is put out to the wider market in a matter of days/weeks at the most.
I'd even bet some of the information put out by Avacta's partners doesn't even hit the desks in Avacta. We've had several postings on here which would have made nice news items for Avacta and we've seen nothing. They can't blame an NDA because the information was made public knowledge by the said company.
BV...I think if they changed him and got someone in who really knew how to communicate then I think the problem might be much improved. As it stands we now have almost two years worth of financing. I'm not sure how long it will take the retail investors to get their new shares but that could be a reason for no news yet.
Experience
Avacta
9 years 10 months
Group Communications Director
Dec 2020 - Present 3 years 4 months
United Kingdom
Leading on corporate communications for Avacta Group, a UK based clinical stage biotech and diagnostics company.
• Creation and execution of Group communications strategy.
• Support senior leadership with considered counsel on reputation related matters and leading issues preparations and response.
• Managing partnerships with a range of advisors and agencies.
• Investor relations and working within the regulatory framework of being a publicly listed company.
• Media relations
Disagree BV...this is the guy they need to get rid of...
https://uk.linkedin.com/in/michaelvinegrad